The University of Chicago Header Logo

Connection

Ravi Salgia to ErbB Receptors

Back to Details
This is a "connection" page, showing publications Ravi Salgia has written about ErbB Receptors.
Ravi Salgia
Connection Strength
4.526
ErbB Receptors
  1. Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy. BMC Cancer. 2018 03 21; 18(1):314.
    View in: PubMed
    Score: 0.511
  2. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One. 2010 Jan 29; 5(1):e8972.
    View in: PubMed
    Score: 0.291
  3. MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. J Environ Pathol Toxicol Oncol. 2009; 28(2):89-98.
    View in: PubMed
    Score: 0.270
  4. EGFR-targeted therapeutics: focus on SCCHN and NSCLC. ScientificWorldJournal. 2008 Sep 21; 8:909-19.
    View in: PubMed
    Score: 0.265
  5. Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res. 2006 Dec 15; 12(24):7261-70.
    View in: PubMed
    Score: 0.234
  6. Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology. 2006 Nov; 11(6):687-92.
    View in: PubMed
    Score: 0.232
  7. Novel therapies in lung cancer. Hematol Oncol Clin North Am. 2005 Apr; 19(2):343-67, vii.
    View in: PubMed
    Score: 0.208
  8. Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor. J Clin Oncol. 2023 02 10; 41(5):1129-1131.
    View in: PubMed
    Score: 0.176
  9. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Chest. 2021 09; 160(3):1095-1107.
    View in: PubMed
    Score: 0.158
  10. Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases. Magn Reson Imaging. 2020 06; 69:49-56.
    View in: PubMed
    Score: 0.147
  11. Precision medicine and actionable alterations in lung cancer: A single institution experience. PLoS One. 2020; 15(2):e0228188.
    View in: PubMed
    Score: 0.146
  12. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Sci Rep. 2017 08 23; 7(1):9192.
    View in: PubMed
    Score: 0.123
  13. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor. Sci Signal. 2017 01 03; 10(460).
    View in: PubMed
    Score: 0.117
  14. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget. 2016 Oct 11; 7(41):66880-66891.
    View in: PubMed
    Score: 0.116
  15. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett. 2016 10 01; 380(2):494-504.
    View in: PubMed
    Score: 0.114
  16. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. Mol Cancer Ther. 2016 09; 15(9):2175-86.
    View in: PubMed
    Score: 0.114
  17. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. Mol Cancer Ther. 2014 May; 13(5):1356-68.
    View in: PubMed
    Score: 0.097
  18. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer. 2013 Jul; 81(1):138-41.
    View in: PubMed
    Score: 0.091
  19. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. J Thorac Oncol. 2012 May; 7(5):856-65.
    View in: PubMed
    Score: 0.085
  20. A novel classification of lung cancer into molecular subtypes. PLoS One. 2012; 7(2):e31906.
    View in: PubMed
    Score: 0.084
  21. Personalized treatment of lung cancer. Semin Oncol. 2011 Apr; 38(2):274-83.
    View in: PubMed
    Score: 0.079
  22. Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res. 2011 Apr 01; 71(7):2423-7.
    View in: PubMed
    Score: 0.078
  23. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist. 2009 Nov; 14(11):1116-30.
    View in: PubMed
    Score: 0.071
  24. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5714-23.
    View in: PubMed
    Score: 0.071
  25. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31.
    View in: PubMed
    Score: 0.068
  26. Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity. Oncogene. 2009 Jan 29; 28(4):518-33.
    View in: PubMed
    Score: 0.067
  27. Tyrosine kinase mutations in human cancer. Curr Mol Med. 2007 Feb; 7(1):77-84.
    View in: PubMed
    Score: 0.059
  28. Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol. 2006 Jan; 3(1):50-7; quiz 1 p following 57.
    View in: PubMed
    Score: 0.055
  29. Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer. 2023 04; 178:166-171.
    View in: PubMed
    Score: 0.045
  30. Role of receptor tyrosine kinases in lung cancer. Methods Mol Med. 2003; 74:113-25.
    View in: PubMed
    Score: 0.044
  31. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002 Sep 15; 62(18):5242-7.
    View in: PubMed
    Score: 0.044
  32. AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer. BMC Cancer. 2022 Apr 23; 22(1):447.
    View in: PubMed
    Score: 0.042
  33. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. J Thorac Oncol. 2021 06; 16(6):1030-1041.
    View in: PubMed
    Score: 0.039
  34. Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem. 2000 Mar 10; 275(10):6868-75.
    View in: PubMed
    Score: 0.037
  35. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6.
    View in: PubMed
    Score: 0.026
  36. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer. 2014 Oct 24; 13:242.
    View in: PubMed
    Score: 0.025
  37. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One. 2014; 9(3):e91577.
    View in: PubMed
    Score: 0.024
  38. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5.
    View in: PubMed
    Score: 0.024
  39. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011 Dec 20; 29(36):4803-10.
    View in: PubMed
    Score: 0.021
  40. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
    View in: PubMed
    Score: 0.016
  41. Key signaling pathways and targets in lung cancer therapy. Clin Lung Cancer. 2007 Feb; 8 Suppl 2:S52-60.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.